Drug Patents owned by Insmed Inc

1. List of Arikayce Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802137 INSMED INC Sustained release of antiinfectives
Apr, 2024

(1 year, 2 months from now)

US9827317 INSMED INC Sustained release of antiinfectives
Apr, 2024

(1 year, 2 months from now)

US7718189 INSMED INC Sustained release of antiinfectives
Jun, 2025

(2 years from now)

US8679532 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
Dec, 2026

(3 years from now)

US8642075 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
Dec, 2026

(3 years from now)

US8632804 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
Dec, 2026

(3 years from now)

US8226975 INSMED INC Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
Aug, 2028

(5 years from now)

US9566234 INSMED INC Systems for treating pulmonary infections
Jan, 2034

(10 years from now)

US11446318 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(12 years from now)

US10251900 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(12 years from now)

US9895385 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(12 years from now)

US10751355 INSMED INC Methods for treating pulmonary non-tuberculous mycobacterial infections
May, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 28, 2025
Generating Antibiotic Incentives Now (GAIN) Sep 28, 2030

Drugs and Companies using AMIKACIN SULFATE ingredient

Market Authorisation Date: 28 September, 2018

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults with cystic fibrosis as part of a combination drug regimen; Treating mycobacterium avium complex (mac) lung disease in non-cystic fibrosis adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic